癌症研究
免疫疗法
免疫系统
抑制器
癌症免疫疗法
核梭杆菌
结直肠癌
封锁
医学
免疫学
阿替唑单抗
免疫检查点
免疫
趋化性
T细胞
信号转导
细胞因子
调节性T细胞
生物
癌症
敏化
免疫耐受
作者
Wenxing Zhang,Chenrui Jin,Shuyuan Liu,Xing Wan,Yu Li,Jiayi Liu,Z.G. Duan,Jingyuan Ma,Yunhai Gao
标识
DOI:10.3389/fimmu.2026.1757513
摘要
Microsatellite-stable (MSS)/proficient mismatch-repair (pMMR) colorectal cancer (CRC) accounts for more than 85% of cases but responds poorly to single-agent immune checkpoint inhibitors (ICIs), with objective response rates remaining below 5%. A principal barrier to effective immunotherapy in these tumors is a durable immunosuppressive axis formed by myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) within the tumor microenvironment. This axis impedes antitumor immunity through multilayered mechanisms including bidirectional chemotactic recruitment, reciprocal cytokine signaling, metabolic suppression and exosome-mediated communication. CRC is uniquely influenced by the gut microbiota: Fusobacterium nucleatum promotes MDSC/Treg enrichment via TLR4-NF-κB and Fap2-TIGIT pathways; Peptostreptococcus anaerobius acts through integrin-PI3K-NF-κB signaling; and microbial metabolites such as 4-HPA activate JAK2/STAT3-CXCL3 signaling to expand MDSC populations. Concurrently, a hypoxia-lactate-HIF-1α-CD73/A2AR circuit further stabilizes suppressive phenotypes, forming a "microbiota-metabolism-hypoxia-MDSC-Treg" cascade. Emerging clinical and translational data indicate that disrupting this axis can sensitize MSS-CRC to ICIs: for example, Zanzalintinib combined with Atezolizumab reported survival benefit in the STELLAR-303 trial, and dual blockade of novel checkpoints with PD-(L)1 has been associated with enhanced immune activation in solid tumors. Targeting the MDSC-Treg axis therefore represents a promising strategy to overcome immunotherapy resistance in MSS/pMMR CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI